Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes
|
|
|
- Bethany Walton
- 5 years ago
- Views:
Transcription
1 Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes Leigh Perreault, MD Associate Professor of Medicine Endocrinology, Metabolism and Diabetes University of Colorado Anschutz Medical Campus Associate Professor of Epidemiology Colorado School of Public Health
2 Disclosures Personal fees for consulting or speaking received from: Novo Nordisk, Merck/Pfizer, Boehringer-Ingelheim/Lilly, Sanofi, Astra Zeneca, Janssen, Medscape, WebMD
3 Trends in age-standardized rates of diabetes-related complications among U.S. adults with diabetes, Cases/10,000 persons Acute MI Stroke Amputation ESRD Death from Acute Hypoglycemia % -67.8% -51.4% -28.3% -64.4% Gregg et al. N Engl J Med 370: , 2014
4
5 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Glucose lowering medications DPP met IDPP met STOP NIDDM acarbose NAVI- GATOR nateg ORIGIN glargine CANOE met/rosi DPP trog DREAM rosi ACT NOW pio 31% 26% 25% -2.1% 20% 27% 1.Knowler, NEJM, Ratner, 2005, Diabetes Care 3. Chiasson, Lancet, NAVIGATOR Study Group NEJM ORIGIN 2012 NEJM 6. Zinnman Lancet Knowler, Diabetes, DREAM Trial Investigators, Lancet DeFronzo NEJM % 60% 72%
6 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Weight loss medications XENDOS orlistat BLOSSOM BLOOM lorcaserin SEQUEL top/phent SCALE liraglutide 45% 36% 89% 79%
7 Slide 6 CW2 MS37 MS51 Dear Leigh - we would like to suggest to change the title of this slide since the objective of trials was not (consistently) to reduce progression of T2. Carolyn Whiting, 10/14/2015 Dr. Perreault: Slide 9: how about the title as Reduction in the Progression to Diabetes: Post-hoc Analyses. Mike Small, 10/20/2015 Dear Dr. Perreault - I've changed the title Mike Small, 10/22/2015 CW19 Dear Leigh, based on some research, we believe there is another top/phent study that did look at progression to T so we may want to replace the SEQUEL value Carolyn Whiting, 10/18/2015 MS38 MS52 CW20 CW21 MS39 MS40 MS53 Dr. Perreault: Totally fine to replace the SEQUEL # if you found another reference. Mike Small, 10/20/2015 Dear Dr. Perreault - I've updated this number Mike Small, 10/22/2015 Dear Leigh - can you please point me in the right direction of the reference for Lorcaserin? Carolyn Whiting, 10/18/2015 Please note, we changed the valude for liraglutide to 80% - can you please tell us where 88% was from? Carolyn Whiting, 10/18/2015 Dr. Perreault: Reference for the locaserin trial was mentioned here: Endocrine Practice June 2015, Vol. 21, No. 6, pp Mike Small, 10/20/2015 Dr. Perreault: ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES Alan J. Garber (doi: /EP14460.RA) Mike Small, 10/20/2015 Dear Dr. Perreault - I've added in this reference Mike Small, 10/22/2015
8 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes MS57 Intensive lifestyle intervention CHINA SWEDEN FINLAND INDIA JAPAN USA 51% 63% 58% 29% 67% 58%
9 Slide 7 MS57 Dear Dr. Perreault - I've updated this slide based on the table below and any new references mentioned in the notes section. The references have been added in as well. Mike Small, 10/22/2015
10
11 Historical Trends in Coronary Heart Disease: Diabetes vs. Prediabetes Perreault, Curr Diab Rep 2017
12 Glucose Lowering Decreases CVD in Pre-diabetes Probability of Any Cardiovascular Event P = 0.04 (Log-Rank test) P = 0.03 (Cox Proportional Model) Placebo Acarbose 49% Days After Randomisation Chiasson, JAMA 2003
13 IRIS N=3876 Recent TIA or stroke HOMA-IR>3 Pio vs. placebo 4.8 year f/u Mean A1c=5.8% Kernan, NEJM 2016
14 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Intensive lifestyle intervention FINLAND: 3.2 years 7 years 10 years 13 years Weight Diabetes CVD 3kg 58% 43% 0% 39% Tuomilehto, NEJM 2001; Lindstrom, Lancet 2006; Uusitupa, Plos One 2009; Lindsrtrom, Diabetologia 2013
15 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Intensive lifestyle intervention and metformin USA: Weight 6 kg 3.2 years Diabetes 31% 58% MET ILS Knowler, NEJM 2002; Knowler, Lancet 2009; Knowler, Lancet 2015
16 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Intensive lifestyle intervention and metformin USA: Weight 3.2 years Diabetes 10 years 6 kg 31% 18% 58% 34% MET ILS Knowler, NEJM 2002; Knowler, Lancet 2009; Knowler, Lancet 2015
17 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Intensive lifestyle intervention and metformin USA: Weight 3.2 years Diabetes 10 years 15 years MVD CAC 6 kg 31% 18% 18% 58% MET 34% 27% 21%* Women in ILS 11%* Men in MET ILS Knowler, NEJM 2002; Knowler, Lancet 2009; Knowler, Lancet 2015
18 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Intensive lifestyle intervention CHINA: 6 years 20 years 23 years Weight Diabetes Retinopathy CV death 1.8 kg 51% 43% 47% 45% 41% Pan, Diab Care 1997; Li, Lancet 2008; Li, Lancet 2014
19 Weight loss in patients with prediabetes reduces longterm incidence of cardiovascular mortality CVD mortality in proportion of participants (%) HR 0.59, 95% CI ( ) Control Intervention Years Cumulative death incidence (%; 95% CI) Intervention (n=430) Control (n=138) Hazard ratio (95% CI) p value All-cause mortality 28.1% ( ) 38.4% ( ) 0.71 ( ) Cardiovascular disease mortality 11.9% ( ) 19.6% ( ) 0.59 ( ) Diabetes incidence 72.6% ( ) 89.9% ( ) 0.55 ( ) Data are n(%) unless stated otherwise. HR, hazard ratios adjusted by clinic. Li et al. Lancet Diabetes Endocrinol 2014;2:474 80
20 Intervention studies for primary prevention of CVD in pre-diabetes Least studies CVD, cardiovascular disease Source: Most studies
21 Can we improve outcomes by changing the shape of the curve?
22 XENDOS Torgerson, Diab Care 2004
23 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Weight loss medications XENDOS: orlistat 4 years Diabetes SBP LDL cholesterol 2.7 kg 45% 5 mmhg 13 mg/dl Torgerson, Diab Care 2004
24 Slide 21 CW2 MS37 MS51 Dear Leigh - we would like to suggest to change the title of this slide since the objective of trials was not (consistently) to reduce progression of T2. Carolyn Whiting, 10/14/2015 Dr. Perreault: Slide 9: how about the title as Reduction in the Progression to Diabetes: Post-hoc Analyses. Mike Small, 10/20/2015 Dear Dr. Perreault - I've changed the title Mike Small, 10/22/2015 CW19 Dear Leigh, based on some research, we believe there is another top/phent study that did look at progression to T so we may want to replace the SEQUEL value Carolyn Whiting, 10/18/2015 MS38 MS52 CW20 CW21 MS39 MS40 MS53 Dr. Perreault: Totally fine to replace the SEQUEL # if you found another reference. Mike Small, 10/20/2015 Dear Dr. Perreault - I've updated this number Mike Small, 10/22/2015 Dear Leigh - can you please point me in the right direction of the reference for Lorcaserin? Carolyn Whiting, 10/18/2015 Please note, we changed the valude for liraglutide to 80% - can you please tell us where 88% was from? Carolyn Whiting, 10/18/2015 Dr. Perreault: Reference for the locaserin trial was mentioned here: Endocrine Practice June 2015, Vol. 21, No. 6, pp Mike Small, 10/20/2015 Dr. Perreault: ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES Alan J. Garber (doi: /EP14460.RA) Mike Small, 10/20/2015 Dear Dr. Perreault - I've added in this reference Mike Small, 10/22/2015
25 BLOOM Smith, NEJM 2010
26 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Weight loss medications BLOSSOM BLOOM: lorcaserin 1 year Diabetes PreT2D SBP LDL cholesterol 2 kg 36% 36% 2 mmhg 2 mg/dl Smith, NEJM 2010, Nesto, Postgrad Med 2016
27 Slide 23 CW2 MS37 MS51 Dear Leigh - we would like to suggest to change the title of this slide since the objective of trials was not (consistently) to reduce progression of T2. Carolyn Whiting, 10/14/2015 Dr. Perreault: Slide 9: how about the title as Reduction in the Progression to Diabetes: Post-hoc Analyses. Mike Small, 10/20/2015 Dear Dr. Perreault - I've changed the title Mike Small, 10/22/2015 CW19 Dear Leigh, based on some research, we believe there is another top/phent study that did look at progression to T so we may want to replace the SEQUEL value Carolyn Whiting, 10/18/2015 MS38 MS52 CW20 CW21 MS39 MS40 MS53 Dr. Perreault: Totally fine to replace the SEQUEL # if you found another reference. Mike Small, 10/20/2015 Dear Dr. Perreault - I've updated this number Mike Small, 10/22/2015 Dear Leigh - can you please point me in the right direction of the reference for Lorcaserin? Carolyn Whiting, 10/18/2015 Please note, we changed the valude for liraglutide to 80% - can you please tell us where 88% was from? Carolyn Whiting, 10/18/2015 Dr. Perreault: Reference for the locaserin trial was mentioned here: Endocrine Practice June 2015, Vol. 21, No. 6, pp Mike Small, 10/20/2015 Dr. Perreault: ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES Alan J. Garber (doi: /EP14460.RA) Mike Small, 10/20/2015 Dear Dr. Perreault - I've added in this reference Mike Small, 10/22/2015
28 SEQUEL Garvey, Diab Care 2014
29 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Weight loss medications SEQUEL top/phent 2 years Diabetes MetS SBP LDL cholesterol 12 kg 89% 19% 5 mmhg 0 mg/dl Garvey, Diab Care 2014
30 Slide 25 CW2 MS37 MS51 Dear Leigh - we would like to suggest to change the title of this slide since the objective of trials was not (consistently) to reduce progression of T2. Carolyn Whiting, 10/14/2015 Dr. Perreault: Slide 9: how about the title as Reduction in the Progression to Diabetes: Post-hoc Analyses. Mike Small, 10/20/2015 Dear Dr. Perreault - I've changed the title Mike Small, 10/22/2015 CW19 Dear Leigh, based on some research, we believe there is another top/phent study that did look at progression to T so we may want to replace the SEQUEL value Carolyn Whiting, 10/18/2015 MS38 MS52 CW20 CW21 MS39 MS40 MS53 Dr. Perreault: Totally fine to replace the SEQUEL # if you found another reference. Mike Small, 10/20/2015 Dear Dr. Perreault - I've updated this number Mike Small, 10/22/2015 Dear Leigh - can you please point me in the right direction of the reference for Lorcaserin? Carolyn Whiting, 10/18/2015 Please note, we changed the valude for liraglutide to 80% - can you please tell us where 88% was from? Carolyn Whiting, 10/18/2015 Dr. Perreault: Reference for the locaserin trial was mentioned here: Endocrine Practice June 2015, Vol. 21, No. 6, pp Mike Small, 10/20/2015 Dr. Perreault: ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES Alan J. Garber (doi: /EP14460.RA) Mike Small, 10/20/2015 Dear Dr. Perreault - I've added in this reference Mike Small, 10/22/2015
31 SCALE Le Roux, Lancet 2017
32 Intervention Trials to Reduce Progression of IGT to Type 2 Diabetes Weight loss medications SCALE liraglutide 3 years Diabetes PreT2D SBP LDL cholesterol 7kg 3 mmhg 0 mg/dl 79% 66% Le Roux, Lancet 2017
33 Slide 27 CW2 MS37 MS51 Dear Leigh - we would like to suggest to change the title of this slide since the objective of trials was not (consistently) to reduce progression of T2. Carolyn Whiting, 10/14/2015 Dr. Perreault: Slide 9: how about the title as Reduction in the Progression to Diabetes: Post-hoc Analyses. Mike Small, 10/20/2015 Dear Dr. Perreault - I've changed the title Mike Small, 10/22/2015 CW19 Dear Leigh, based on some research, we believe there is another top/phent study that did look at progression to T so we may want to replace the SEQUEL value Carolyn Whiting, 10/18/2015 MS38 MS52 CW20 CW21 MS39 MS40 MS53 Dr. Perreault: Totally fine to replace the SEQUEL # if you found another reference. Mike Small, 10/20/2015 Dear Dr. Perreault - I've updated this number Mike Small, 10/22/2015 Dear Leigh - can you please point me in the right direction of the reference for Lorcaserin? Carolyn Whiting, 10/18/2015 Please note, we changed the valude for liraglutide to 80% - can you please tell us where 88% was from? Carolyn Whiting, 10/18/2015 Dr. Perreault: Reference for the locaserin trial was mentioned here: Endocrine Practice June 2015, Vol. 21, No. 6, pp Mike Small, 10/20/2015 Dr. Perreault: ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES Alan J. Garber (doi: /EP14460.RA) Mike Small, 10/20/2015 Dear Dr. Perreault - I've added in this reference Mike Small, 10/22/2015
34 Long-term weight loss in prediabetes doesn t just prevent diabetes
35 Drug: 52 wk exposure Phentermine Pharmacologic Weight Loss Placebo subtracted weight loss 5 kg* Orlistat Phentermine/topiramate Lorcaserin QD-BID Naltrexone/buproprion Liraglutide 3.0 mg 3 kg 8.7 kg 3.6 kg 4.8 kg 5.6 kg Munro, BMJ 1968; LeBlanc, Ann Int Med 2011; Gadde, Lancet 2011; Smith, NEJM 2010; Greenway, Lancet 2010; Pi-Sunyer, NEJM 2015
36 Pharmacologic Weight Loss Drug: 52 wk exposure Placebo subtracted Actual weight loss weight loss Phentermine 9 kg* 12.7 kg* *36-weeks Orlistat 3 kg 5.8 kg Phentermine/topiramate 8.7 kg 10 kg Lorcaserin QD-BID 3.6 kg 5.8 kg Naltrexone/buproprion 4.8 kg 6.1 kg Liraglutide 3.0 mg 5.6 kg 8 kg Munro, BMJ 1968; LeBlanc, Ann Int Med 2011; Gadde, Lancet 2011; Smith, NEJM 2010; Greenway, Lancet 2010; Pi-Sunyer, NEJM 2015
37 Minimal weight loss in placebo arm: LOOK AHEAD Wing, Arch Int Med 2010; Pi-Sunyer, Diab Care 2007; Bray, Diab Vasc Dis Res 2006
38 Minimal weight loss in placebo arm: The Diabetes Prevention Program and Outcomes Study Knowler,Lancet 2009
39 BLOOM Smith, NEJM 2010
40 Classic Placebo Concept cohort placebo randomization active drug measured outcome some response greater response
41 The Placebo Effect Expectation Desire Conditioning* *common but not essential Vase, Psych Mod Pain 2004
42 Expectation post-op pain medication administered by person vs. machine Amanzio, Pain 2001
43 Desire 29% placebo response 45% active drug response Both increasing over time Walsh, JAMA 2002
44 Pecina, JAMA 2015
45 Desire Placebo Effect: Neuroscience Dopamine response to placebo in Parkinson s disease Before After } +20% Before After } 16% improved Dopamine release (PET) Motor function (blinded clinical exam) De la Fuente-Fernandez, Science 2001; Goetz, Neurol 2000
46 Conditioning Cyclosporine on IFN- in multiple sclerosis Goebel, Faseb 2002
47 Conditioning Cyclosporine on IFN- in multiple sclerosis Change from baseline (%) Cyclosporine before Conditioned effect re-exposure effect Goebel, Faseb 2002
48 Weight loss medications appetite suppressants Phentermine Topiramate Locaserin Buproprion / naltrexone Farooqi, Cell Metab 2006
49 The Placebo Effect Expectation Desire Conditioning* *common but not essential Vase, Psych Mod Pain 2004
50 Conclusions Modest - and often transient - weight loss achieved by lifestyle modification can delay diabetes. It also lowers complications of diabetes, but it takes years to see the benefits. Weight loss achieved through pharmacotherapy has also been shown to prevent or delay diabetes. Might these medications also prevent diseases and more robustly - associated with obesity and diabetes?
Why Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
Lorcaserin (Belviq ) Rimonabant 2008 Sibutramine (Reductil, ) (World Health organization, WHO) 1996 WHO Orlistat (Xenical, )
(World Health organization, WHO) 1996 WHO (Body mass index, BMI)2427 kg/m 2 27 kg/m 2 25% 30%2013-2014 43.5%(48.9%38.3%) (AACE/ACE)2016 1 BMI 27 kg/m 2 BMI 35 kg/m 2 (The Food and Drug Administration,
Copyright 2017 by Sea Courses Inc.
Pre-Diabetes: Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical,
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease
: Early Diagnosis and Treatment to Prevent Cardiovascular Disease Henry N. Ginsberg, M.D. Irving Professor of Medicine Columbia University College of Physicans and Surgeons The Metabolic Syndrome: Early
Prediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
Implementing Type 2 Diabetes Prevention Programmes
Implementing Type 2 Diabetes Prevention Programmes Jaakko Tuomilehto Department of Public Health University of Helsinki Helsinki, Finland FIN-D2D Survey 2004 Prevalence of previously diagnosed and screen-detected
The Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
Type 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
OBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
The New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
Primary Prevention of T2DM. KW Chan Endocrine & Diabetes Team Department of M&G, PMH 22 March 2009
Primary Prevention of T2DM KW Chan Endocrine & Diabetes Team Department of M&G, PMH 22 March 2009 Primary Prevention of T2DM Why to intervene? When to intervene? Lifestyle intervention Pharmacological
Non-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
Why Do We Treat Obesity? Metabolic Complications
Why Do We Treat Obesity? Metabolic Complications 2 Metabolic Complications of Obesity Diabetes Risk 3 Criteria for Diagnosis of the Metabolic Syndrome Characteristic Waist circumference Triglycerides HDL-C
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
Glucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
COMBINATION OF PHENTERMINE/TOPIRAMATE ER AND LIRAGLUTIDE 3MG FOR INTENSIVE THERAPY OF SEVERE OBESITY & T2DM A CASE SERIES AND BRIEF REVIEW
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After
Cedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
Preventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
A Heavy Burden: Obesity and Diabetes" Diabetes In and Out University of Rochester School of Medicine and Dentistry March 12, 2016
A Heavy Burden: Obesity and Diabetes" Diabetes In and Out University of Rochester School of Medicine and Dentistry March 12, 2016 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and
Disclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014
Disclosures Behavioral and Medical Approaches for Obesity Treatment Scott Kahan, MD, MPH Director, National Center for Weight and Wellness Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity
The Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease
Percent 4 3 2 1 Obese Overweight Extremely obese Note: Age-adjusted by the direct method to the year 2 US Bureau of the Census using age groups 2 39, 4 59, and 6 74 years. Pregnant females excluded. Overweight
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
Diabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
Diabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
Diabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
Cardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
Microvascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
CANA DAPA EMPA. Change in Baseline Body Weight (kg) *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg, EMPA=10 or 25 mg.
CANA DAPA EMPA Change in Baseline Body Weight (kg) 2 1 0-1 -2-3 -4-5 PBO SGLT2 inhibitor (low dose)* SGLT2 inhibitor (high dose)* *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg,
Actualités en diabétologie Quoi de neuf en 2016? S. Aouiche Service de diabétologie CHU Mustapha Alger.Pr BOUDIBA
Actualités en diabétologie Quoi de neuf en 2016? S. Aouiche Service de diabétologie CHU Mustapha Alger.Pr BOUDIBA Deux médicaments valent mieux qu un dans le traitement du patient diabétique Jochen.SEUFERT
Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
Early treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
Approach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
Prevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine
Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer
Energy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
Diabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
Targeting Glucose Metabolism to Stop Strokes IRIS: Insulin Resistance In Stroke study
Targeting Glucose Metabolism to Stop Strokes IRIS: Insulin Resistance In Stroke study Professor Gary Ford Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford
The Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
Contents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies
Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance
Multi-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
The US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest CLASSIFICATION OF OVERWEIGHT
Learning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD
Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms
Du gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
Microvascular complications in the metabolic syndrome
Microvascular complications in the metabolic syndrome Dr. Chih Hao Chen Ku, FACE Endocrinology Department, San Juan de Dios Hospital Clinical Pharmacology and Toxicology Department, University of Costa
Disclosures. Obesity and the Continuum of Dysglycemia, Prediabetes and Diabetes OUTLINE
Obesity and the Continuum of Dysglycemia, Prediabetes and Diabetes Sam Dagogo-Jack, MD, DM, FRCP A. C. Mullins Endowed Chair in Translational Research Professor of Medicine & Director Division of Endocrinology,
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
Type 2 Diabetes in Adolescents
Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic
Faculty. Identification and Treatment of Prediabetes to Prevent or Delay the Onset of T2DM. Learning Objectives. Disclosures
Faculty Identification and Treatment of Prediabetes to Prevent or Delay the Onset of Sam Dagogo-Jack, MD, DM, FRCP A. C. Mullins Endowed Chair in Translational Research Professor of Medicine & Director
Know what s ahead the earlier, the better
Cardio IQ Insulin Resistance Panel with Score Know what s ahead the earlier, the better Detecting insulin resistance now can help you and your patients take action to change its course Put your patients
Obesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH
Obesity Pharmacotherapy: Options and Applications in Clinical Practice Scott Kahan, MD, MPH Obesity Pharmacotherapy Few providers prescribe pharmacotherapy. Few patients use pharmacotherapy. Pharmacotherapy
Update on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
Update on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
Presenter Disclosure Information
Prediabetes & Type 2 Diabetes Prevention Cari Ritter, PA-C Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
Regulatory Hurdles for Drug Approvals
Regulatory Hurdles for Drug Approvals William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research 25 min Conflicts CPC Clinical Research
3/11/2019. Debate: A Conversation on Weight Management and Health at Every Size. Defining Obesity. Obesity: In the top three global social burdens
Foundational Concepts Debate: A Conversation on Weight Management and Health at Every Size Robert F. Kushner, MD, MS Professor of Medicine Northwestern University Feinberg School of Medicine Director,
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
Medical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
DIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
CVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
Glucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
T2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
Microvascular complications in the metabolic syndrome
Microvascular complications in the metabolic syndrome Dr. Chih Hao Chen Ku, FACE Endocrinology Department, San Juan de Dios Hospital Clinical Pharmacology and Toxicology Department, University of Costa
Management of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
Obesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
NEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
Update on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine
Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy Shelby Sullivan University of Colorado School Of Medicine Disclosures Research Support / Grants R01DK094483-02 Klein/Mittendorfer
Obesity: Pharmacologic and Surgical Management
Obesity: Pharmacologic and Surgical Management ADRIENNE YOUDIM, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE, UCLA ASSISTANT PROFESSOR OF MEDICINE, CEDARS SINAI MEDICAL CENTER JANUARY 2018 Defining Obesity
No Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
Diabetes Risk Assessment and Treatment
Diabetes Risk Assessment and Treatment Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University Baltimore, Maryland, USA
Evidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
Type 2 diabetes and cardiovascular risk: the role of GLP-1
Type 2 diabetes and cardiovascular risk: the role of GLP-1 Dr Isidora Kitsou-Mylona, PhD Novo Nordisk Regional Medical Advisor Business Area Africa, Gulf & India Disclaimer I am an employee of Novo Nordisk
The Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
Diabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1172-3 Program Prior Authorization - California and New York Regulatory Program - Weight Loss Medication Includes both brand and
Session 4: Obesity and Type 2 Diabetes: Understanding the Benefits of Weight Loss in the Diabetic Population
Session 4: Obesity and Type 2 Diabetes: Understanding the Benefits of Weight Loss in the Diabetic Population Learning Objectives 1. Recognize the impact of excess weight on overall patient health and the
Metformin. Sulfonylurea. Thiazolidinedione. Insulin
동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial
Antihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
AMERICAN COLLEGE OF ENDOCRINOLOGY TASK FORCE ON PRE-DIABETES
AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS STATEMENT ON THE DIAGNOSIS AND MANAGEMENT OF PRE-DIABETES IN THE CONTINUUM OF HYPERGLYCEMIA WHEN DO THE RISKS OF DIABETES BEGIN? AMERICAN COLLEGE OF ENDOCRINOLOGY
Reducing cardiovascular risk factors in patients with prediabetes
REVIEW Reducing cardiovascular risk factors in patients with prediabetes Jean-Louis Chiasson 1 & Sophie Bernard 1 Practice Points The prevalence of prediabetes is high and on the rise. Subjects with impaired
Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
1:55-2:4pm Medical Management of Obesity: Lifestyle, Medicine, and Surgery SPEAKER Osama Hamdy, MD, PhD, FACE Disclosures The following relationships exist related to this presentation: Osama Hamdy, MD,
Let s s start with a case study.
Disclosure Dr. Ryan has received financial remuneration in 2015 from Amgen, Novo Nordisk, Janssen, Pfizer, Takeda, Vivus, Real Appeal, and Scientific Intake. Medicating the Patient with Obesity Clinical